PGI26 FINANCIAL IMPACT OF LIFTING A PRIOR AUTHORIZATION ON LUBIPROSTONE FOR CHRONIC CONSTIPATION PATIENTS IN A COMMERCIAL MANAGED CARE POPULATION (AGE < 65 YEARS)  by Lobo, F et al.
and severe (n = 25; 31%). CONCLUSION: Constipation was
reported by approximately 25% of the hospice patients, a third
of whom rated their constipation as severe. A substantial number
of hospice patients may require aggressive management of con-
stipation. This information may be useful as a process indicator
of quality of care.
GASTROINTESTINAL DISORDERS—Health Care Use &
Policy Studies
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OBJECTIVE: Assess knowledge and care seeking behaviors
for gastro-esophageal reﬂux disease via a population-based
approach. Identify variations in knowledge, attitude, and care
seeking patterns between racial groups, while also investigating
socio-economic disparities. METHODS: A questionnaire based
upon previous work (Srinivansin, J Clin Gastro) was developed
to assess knowledge, attitudes, and care seeking patterns for
GERD and was translated into Chinese and Spanish. We worked
with community and faith-based leaders to identify events for
data collection. Four ethnic groups (White, Black, Asian, His-
panic) were compared. All descriptive and multivariate analyses
were done using SAS 9.1. RESULTS: Although Hispanics had the
highest prevalence rate for GERD, their familiarity with the
condition was lower (61.2%), compared to Whites (68.9%) and
Blacks (63.7%); Asians were the least familiar with GERD
(44.6%) (P < 0.0001). There was a positive correlation between
increased education level and awareness for GERD (P < 0.0001).
In general, Whites were the most likely to recognize GERD
symptoms and behaviors to control GERD, while Asians were
the least likely. Blacks and Hispanics were more likely to go to
the Emergency Room for severe heartburn compared to Asians
and Whites (P < 0.0001). Asians were least likely to go see a
doctor when presented with a complication of heartburn
(P < 0.0001). A total of 40.8% of Asians and 35.5% of Hispan-
ics indicated that cost and the lack of health insurance would
prevent them from seeing a doctor, higher rates than Whites and
Blacks (P = 0.0073). CONCLUSION: Minorities lack an equal
understanding of GERD, compared to Whites. Asians were par-
ticularly inaccurate in assessing symptoms for GERD and were
least likely to see a doctor. Further research should focus on
improving minority understanding of GERD symptoms and at
what point to consult a physician. The impact of cost and lack of
insurance on care seeking behaviors amongst Hispanics and
Asians should also be examined.
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OBJECTIVE: To examine pharmacy costs of a Prior Authoriza-
tion (PA) on lubiprostone for elderly chronic constipation (CC)
patients in a Medicare Part-D plan. METHODS: Cost impact of
PA was calculated by estimating annual pharmacy cost differ-
ences with PA (PA administration costs + medication costs) and
without PA (medication costs only). Model inputs included pub-
lished estimates of CC prevalence; lubiprostone utilization from
IMS Health, 2007; average PA approval rate, PA costs and
co-payment from payer interviews; and lubiprostone wholesale
acquisition costs. Annual medication costs in both scenarios
included costs and utilization of lubiprostone less co-payment,
assuming third-tier placement for lubiprostone. All previously
rejected prescriptions were assumed to be approved after lifting
PA, resulting in 21.24% increase in prescription volume. Sensi-
tivity analyses were performed on PA cost, PA approval rate,
and expected increase in prescription volume after lifting PA.
RESULTS: CC prevalence was 14.7%, of which 1.14% were
lubiprostone users. For a 1-million member plan, this resulted in
1264 PA requests costing $27 each. Annual cost of PA adminis-
tration was $34,130. PA approval rate for the elderly was 77.7%
(or 982 approved users). Average number of ﬁlls per person per
year was 3.8. A 30-day lubiprostone prescription costed $28.40
($86.40 WAC-$60 co-payment + $2 dispensing fee). Drug costs
were $105,997, resulting in total annual cost with PA of
$140,127. Total annual costs without PA were $128,506, based
on an additional 209 users, resulting in annual savings of
$11,621. Sensitivity analyses indicated break even scenarios from
removing PA on lubiprostone when cost per PA > $17.81 or PA
approval rate > 69.18%, or expected increase in prescriptions
from lifting PA < 32.20%. CONCLUSIONS: PA program for
lubiprostone offers no ﬁnancial savings to a Medicare plan based
on current approval rates and annual utilization for elderly
patients with CC in the base case as well as in sensitivity analyses.
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OBJECTIVE: To examine pharmacy costs of a Prior Authoriza-
tion (PA) restriction on lubiprostone for chronic constipation
(CC) patients in a commercial managed care plan. METHODS:
Cost impact of PA was calculated by estimating annual pharmacy
cost differences with PA (medication costs + PA administration)
and without PA (medication costs only). Model inputs included
CC prevalence estimates from the literature; lubiprostone utili-
zation from IMS Health, 2007; average PA approval rate, PA
costs and co-payment from managed care interviews; and lubi-
prostone wholesale acquisition costs. Annual medication costs in
both scenarios included costs and utilization of lubiprostone less
co-payment, assuming third-tier placement for lubiprostone. All
previously rejected prescriptions were assumed to be accepted
after lifting PA, resulting in 11.36% increase in prescription
volume. Sensitivity analyses were performed on cost per PA, PA
approval rate, and expected increase in prescription volume
after lifting PA. RESULTS: CC prevalence was 14.7%, of which
1.14% were lubiprostone users. For a 1-million member plan,
this resulted in 1264 PA requests costing $27 each. Annual cost
of PA administration was $34,130. PA acceptance rate was
81.90% (or 1035 approved users). Average number of ﬁlls per
person per year was 3.8. A 30-day lubiprostone prescription
costed $43.40 ($86.40 WAC-$45 co-payment + $2 dispensing
fee). Drug costs were $170,737, resulting in total annual cost
with PA of $204,867. Total costs without PA were $190,125,
based on additional 118 approved users, resulting in annual
savings of $14,742. Sensitivity analyses indicated break even
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scenarios from removing a PA on lubiprostone when cost per PA
>$15.34 or PA approval rate >74.83%, or expected increase in
prescriptions from lifting PA <19.99%. CONCLUSION: PA
program for lubiprostone offers no ﬁnancial savings to a health
plan based on current approval rates and annual utilization for
patients suffering from CC in the base case as well as in sensi-
tivity analyses.
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OBJECTIVE: Access the Brazilian inﬂammatory bowel diseases
patients’ proﬁle METHODS: A retrospective database study was
performed in 23 IBD treatment centers in 14 Brazilian reference
cities. The centers collected data from the last 5 years about
personal data, disease important aspects (like race and smoking
habits), diagnosis and disease treatment. RESULTS: A total of
2529 medical records were analyzed. Crohnxs disease was the
most prevalent (49%) IBD. Sixty-ﬁve percent of the patients are
Caucasian and 9% are smokers. The median weight of the
patients are 62.5 kg and the median age 40.18% of the patients
came to the actual medical center with a previous IBD diagnostic
and 64% of this diagnosticated group came with a previous
treatment. CONCLUSION: This is the ﬁrst time that signiﬁcant
information about the Brazilian IBD patient proﬁle is evaluated.
Knowledge of the IBD could be a useful tool for supply policy
interventions. Combined with clinical data, this patient proﬁle
could contribute to the qualitative and quantitative evaluation of
disease management policy for this group pf illness.
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OBJECTIVE: To quantify preferences that ulcerative colitis (UC)
patients place on treatment attributes when making therapy
choices. METHODS: A telephonic survey of patients with
UC > 18 years old who requested information from the website
www.LivingWithUC.com from January to April 2006. Patients
were presented with nine factors that might impact a UC
patient’s decision-making process regarding whether to use a
biologic medication such as inﬂiximab. A discreet choice meth-
odology was employed using a complete block design, which
presented 9 factors being tested in 36 discreet pairs and patients
were asked to select the more important factor from each pair
presented. RESULTS: A total of 427 UC patients were contacted
to get 294 completed interviews. The median age was 50 years
and 204 (69.4%) were female. Of respondents currently on
medication, 71% indicated their symptoms were under control
and 75% of these respondents were experiencing 2 ﬂares per
year. One third (34%) of respondents classiﬁed their UC as being
moderate to severe. When asked about treatment options pre-
sented by their doctor, 42% had discussed surgery and 18% said
doctors indicated surgery was a cure for UC. Half (50%) recalled
their doctor presenting only one drug option, and of those pre-
sented with several options, 20% recall the physician emphasiz-
ing a particular drug. Respondents indicated healing the damage
of the intestinal lining (74%) and avoiding surgery (73%) were
important characteristics when deciding to use a product like
inﬂiximab to treat UC. Method of administration (23%) and cost
of co-pay (19%) were given least importance. CONCLUSION:
While doctors may focus on surgery as a cure for UC, patients in
this study state healing intestinal damage and avoiding surgery
would be their most important reasons to use a medication.
Doctors and patients may need to discuss a wider variety of
therapeutic options for treating UC before surgery is considered.
INFECTION—Clinical Outcomes Studies
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OBJECTIVE: The Ontario Addiction Treatment Centres
(OATC) operates 26 clinics offering methadone maintenance
treatment (MMT) to clients with a dependence on opiates. Until
recently, MMT was a contraindication to antiviral therapy for
the treatment of Hepatitis C virus (HCV) infected patients. The
purpose of this study was 1) to describe a care model for treating
HCV infected MMT clients in a community-based setting, 2) to
describe clinical and demographic characteristics of these clients,
3) to assess rates of adherence to antiviral therapy, and 4) to
assess rates of sustained virological response (SVR). METHODS:
A review of patient medical records was employed. Clients con-
sidered for antiviral therapy at the OATC had achieved “func-
tional stability”, characterized by stable housing and a low
frequency of substance abuse, in addition to meeting clinical
criteria. Clients were followed by a hepatitis nurse, clinic physi-
cian or infectious disease specialist at the clinic where they
received methadone. Use of illicit substances was monitored
before, during and after antiviral therapy with regular urinalysis.
RESULTS: Between November 2002 and January 2006, 109
clients (75 with genotype 1/4 and 33 with genotype 2/3) received
at least one injection with pegylated interferon. The majority of
clients were single (60%), living in a permanent apartment or
house (94%), with a high frequency of self-reported psychiatric
disorders (68%). A large proportion had a criminal history
(71%) and many had been incarcerated (52%). Rates of adher-
ence to treatment of 57% and 70% were achieved for genotypes
1/4, and 2/3, respectively. Rates of SVR in an intention to treat
analysis were 51% for genotypes 1/4 and 64% for genotypes 2/3.
Six clients discontinued therapy due to on-going problems with
substance abuse. CONCLUSION: HCV antiviral therapy for
current or former substance abusers can be successful in the
context of specialized care for substance abuse.
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OBJECTIVE: To systematically review the effectiveness of pegy-
lated interferon (PEG), lamivudine (LAM), adefovir (ADF) and
entecavir (ENT) in treating CHB. METHODS: Pubmed, Embase,
Cochrane, and Econlit were searched for randomized controlled
trials assessing the efﬁcacy of the selected drugs for treating CHB
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